As more employers invest in fertility-related benefits, they are focusing on such offerings as fertility medications, in-vitro fertilization and non-IVF treatments.
With concerns about rapidly rising costs, this is the first time in many years that mental health is not employers' top employee benefits priority for the year ahead.
The 'staggering' cost of pharmacy drugs is driving most of the increase, says Ellen Kelsay of the Business Group on Health, which released new data this week.
A handful of these voluntary benefits are perennial favorites with employers, while others, like identity theft protection plans, are gaining steam among offerings.
The FDA's decision on Aug. 9, 2024, not to approve MDMA to treat PTSD marks a blow to a small but growing number of employers offering healthcare coverage for psychedelic drugs to treat mental health issues like depression.
Awareness and access remain obstacles preventing lower-income workers from taking advantage of employee wellbeing benefits. Experts share what HR can do.
